Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Outcomes of Nocardiosis and Treatment of Disseminated Infection in Solid Organ Transplant Recipients

View through CrossRef
Background. Nocardia is an environmental pathogen with a predilection for causing opportunistic infections in immunocompromised patients, including solid organ transplant (SOT) recipients. Although risk factors have been identified for developing nocardiosis in this population, little is known regarding clinical factors resulting in poor outcomes. We evaluated a cohort of SOT recipients with nocardiosis for associations with 12-month mortality. Methods. We performed a multicenter retrospective cohort study of adult SOT recipients diagnosed with culture-confirmed nocardiosis from 2000 to 2020. Patients were followed for 12 months after diagnosis, unless abbreviated by mortality. Multivariable Cox regression was performed to analyze associations with 12-month mortality. A subgroup analysis of patients with disseminated nocardiosis was performed to analyze treatment variables. Results. A total of 125 SOT recipients met inclusion criteria; 12-month mortality was 16.8%. Liver transplantation (hazard ratio [HR] 3.52; 95% confidence interval [CI] 1.27-9.76) and time from symptom onset to presentation (HR 0.92/d; 95% CI 0.86-0.99) were independently associated with 12-month mortality, whereas disseminated infection was not (HR 1.23; 95% CI 0.49-3.13). No treatment-specific factors were significantly associated with mortality in 33 patients with disseminated nocardiosis, although survivors had a higher rate of linezolid use. Conclusions. This study identified 2 independent associations with 12-month mortality, representing demographics and infection severity. Disseminated infection was not independently associated with poor outcomes, and specific sites of infection may be more important than dissemination itself. No treatment-specific factors were associated with mortality, though this analysis was likely underpowered. Further study of treatment strategies based on specific Nocardia syndromes is warranted.
Title: Outcomes of Nocardiosis and Treatment of Disseminated Infection in Solid Organ Transplant Recipients
Description:
Background.
Nocardia is an environmental pathogen with a predilection for causing opportunistic infections in immunocompromised patients, including solid organ transplant (SOT) recipients.
Although risk factors have been identified for developing nocardiosis in this population, little is known regarding clinical factors resulting in poor outcomes.
We evaluated a cohort of SOT recipients with nocardiosis for associations with 12-month mortality.
Methods.
We performed a multicenter retrospective cohort study of adult SOT recipients diagnosed with culture-confirmed nocardiosis from 2000 to 2020.
Patients were followed for 12 months after diagnosis, unless abbreviated by mortality.
Multivariable Cox regression was performed to analyze associations with 12-month mortality.
A subgroup analysis of patients with disseminated nocardiosis was performed to analyze treatment variables.
Results.
A total of 125 SOT recipients met inclusion criteria; 12-month mortality was 16.
8%.
Liver transplantation (hazard ratio [HR] 3.
52; 95% confidence interval [CI] 1.
27-9.
76) and time from symptom onset to presentation (HR 0.
92/d; 95% CI 0.
86-0.
99) were independently associated with 12-month mortality, whereas disseminated infection was not (HR 1.
23; 95% CI 0.
49-3.
13).
No treatment-specific factors were significantly associated with mortality in 33 patients with disseminated nocardiosis, although survivors had a higher rate of linezolid use.
Conclusions.
This study identified 2 independent associations with 12-month mortality, representing demographics and infection severity.
Disseminated infection was not independently associated with poor outcomes, and specific sites of infection may be more important than dissemination itself.
No treatment-specific factors were associated with mortality, though this analysis was likely underpowered.
Further study of treatment strategies based on specific Nocardia syndromes is warranted.

Related Results

Nocardiosis in tropical renal transplant recipients
Nocardiosis in tropical renal transplant recipients
Background: The epidemiology of nocardiosis in the tropics among renal transplant recipients has not been reported.Methods: An evaluation of nocardiosis for 30 yr in one of the lar...
Hepatitis E Viraemia in Transplant Recipients
Hepatitis E Viraemia in Transplant Recipients
Abstract Introduction: Hepatitis E Virus (HEV) is one of the leading causes of acute infectious hepatitis worldwide; while usually a s...
Single Center Analysis of Incidence and Outcome of COVID-19 Infection in Solid Organ Transplant Recipients
Single Center Analysis of Incidence and Outcome of COVID-19 Infection in Solid Organ Transplant Recipients
Aim: To determine overall mortality, outcome and mortality of COVID 19 infection in solid organ transplant pts. Study design: Retrospective study. Place and duration of study: Depa...
Percutaneous Coronary Intervention Outcomes in Solid Organ Transplant Candidates
Percutaneous Coronary Intervention Outcomes in Solid Organ Transplant Candidates
Background: As part of the pre-transplant assessment, patients with end-stage renal, liver, pancreas, or lung disease who wish to attain transplant eligibility must undergo evaluat...
SARS-CoV-2-Specific Antibodies, B Cell and T Cell Immune Responses after ChAdOx1 nCoV-19 Vaccination in Solid Organ Transplant Recipients
SARS-CoV-2-Specific Antibodies, B Cell and T Cell Immune Responses after ChAdOx1 nCoV-19 Vaccination in Solid Organ Transplant Recipients
Background: Immunization against SARS-CoV-2 is essential for vulnerable solid organ transplant (SOT) recipients who are at risk of infection. However, there are concerns about subo...
The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy
The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy
AbstractIntroductionSince the start of the COVID‐19 pandemic, data published on the immunogenicity of the SARS‐CoV‐2 BNT 162B2 vaccine in pediatric patients receiving renal replace...

Back to Top